Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.45 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22059962 | 1.00 | KDM4E (0.46) | KDM4EOPRL1PROKR1NR3C2HDAC1 | |
| SCHEMBL20757256 | 0.87 | KDM4E (0.48) | KDM4ENR3C2HDAC1HDAC2USP30 | |
| SCHEMBL20757938 | 0.86 | KDM4E (0.47) | KDM4EOPRL1HDAC1HDAC2USP30 | |
| SCHEMBL19202529 | 0.86 | ESR2 (0.51) | KDM4EUSP30CNR1MEN1KMT2A | |
| SCHEMBL20757935 | 0.85 | KDM4E (0.46) | KDM4EHDAC1HDAC2USP30MEN1 | |
| SCHEMBL23623173 | 0.85 | USP30 (0.48) | KDM4EUSP30CNR1MEN1KMT2A | |
| SCHEMBL30912590 | 0.85 | NR1H2 (0.49) | KDM4EHDAC1HDAC2USP30CNR1 | |
| SCHEMBL30416827 | 0.85 | USP30 (0.48) | KDM4EUSP30CNR1MEN1KMT2A | |
| SCHEMBL38658196 | 0.84 | GPR119 (0.46) | KDM4EUSP30CNR1MEN1KMT2A | |
| SCHEMBL25305715 | 0.83 | HDAC1 (0.45) | KDM4EHDAC1HDAC2NTRK1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2023247670-A1 | NEW HETEROCYCLIC-CARBONYL-CYCLIC COMPOUNDS AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | KDM4E 1137/4885OPRL1 18/4885PROKR1 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.